🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 19/04/1994 | 6,50 | 6,88 | 6,25 | 6,44 | -2,83% | 9,62% | 133.600 |
| 18/04/1994 | 6,88 | 6,88 | 6,63 | 6,63 | -3,64% | 3,64% | 49.600 |
| 15/04/1994 | 6,88 | 6,88 | 6,63 | 6,88 | +3,77% | 3,64% | 28.200 |
| 14/04/1994 | 6,63 | 7,00 | 6,63 | 6,63 | -5,36% | 5,66% | 63.000 |
| 13/04/1994 | 7,25 | 7,25 | 6,63 | 7,00 | +0,00% | 8,62% | 120.600 |
| 12/04/1994 | 7,56 | 7,56 | 7,00 | 7,00 | -5,08% | 7,44% | 47.400 |
| 11/04/1994 | 7,50 | 7,75 | 7,38 | 7,38 | +0,00% | 5,00% | 88.400 |
| 08/04/1994 | 7,25 | 7,75 | 7,25 | 7,38 | -3,28% | 6,90% | 63.600 |
| 07/04/1994 | 7,13 | 7,63 | 6,75 | 7,63 | +9,91% | 12,28% | 116.000 |
| 06/04/1994 | 7,13 | 7,13 | 6,75 | 6,94 | -1,77% | 5,26% | 227.400 |
| 05/04/1994 | 6,75 | 7,13 | 6,38 | 7,06 | +4,63% | 11,11% | 56.400 |
| 04/04/1994 | 6,50 | 6,75 | 6,25 | 6,75 | +0,93% | 7,69% | 65.600 |
| 31/03/1994 | 6,38 | 6,69 | 6,06 | 6,69 | +9,18% | 9,80% | 312.000 |
| 30/03/1994 | 6,38 | 6,50 | 6,13 | 6,13 | -5,77% | 5,88% | 175.600 |
| 29/03/1994 | 6,50 | 6,81 | 6,38 | 6,50 | -1,89% | 6,73% | 470.800 |
| 28/03/1994 | 7,13 | 7,13 | 6,63 | 6,63 | -7,02% | 7,02% | 299.600 |
| 25/03/1994 | 7,38 | 7,38 | 6,88 | 7,13 | +1,79% | 6,78% | 383.000 |
| 24/03/1994 | 7,63 | 7,75 | 6,69 | 7,00 | -8,20% | 13,93% | 241.800 |
| 23/03/1994 | 7,63 | 7,88 | 7,63 | 7,63 | -3,17% | 3,28% | 117.600 |
| 22/03/1994 | 7,63 | 8,00 | 7,63 | 7,88 | +0,00% | 4,92% | 55.400 |
| 21/03/1994 | 7,75 | 8,00 | 7,75 | 7,88 | +0,80% | 3,23% | 22.000 |
| 18/03/1994 | 8,00 | 8,00 | 7,63 | 7,81 | -2,34% | 4,69% | 158.400 |
| 17/03/1994 | 8,00 | 8,00 | 7,63 | 8,00 | +4,07% | 4,69% | 79.800 |
| 16/03/1994 | 7,75 | 7,88 | 7,63 | 7,69 | -2,38% | 3,23% | 87.800 |
| 15/03/1994 | 8,00 | 8,13 | 7,75 | 7,88 | -3,08% | 4,69% | 173.200 |
| 14/03/1994 | 8,00 | 8,25 | 8,00 | 8,13 | +0,00% | 3,13% | 143.200 |
| 11/03/1994 | 8,13 | 8,38 | 8,13 | 8,13 | -2,99% | 3,08% | 105.000 |
| 10/03/1994 | 8,13 | 8,38 | 8,13 | 8,38 | +0,00% | 3,08% | 26.200 |
| 09/03/1994 | 8,25 | 8,38 | 8,13 | 8,38 | +0,00% | 3,03% | 230.200 |
| 08/03/1994 | 8,38 | 8,63 | 8,25 | 8,38 | -0,74% | 4,48% | 314.200 |